Dr. Endsley joined Certara in October 2018 as Director, Integrated Drug Development. Aaron received a BS in Microbiology, and PhD in Pharmaceutics from University of Washington where his thesis research focused on pharmacokinetics and targeted liposomal drug delivery of anti-HIV drugs. He has held positions at Bayer HealthCare in the Bioanalytics and Phamacokinetics group, and SRI International in both the Drug Delivery and DMPK groups, where he has supported the progression of a diverse range of internal and client/partner small and large molecule candidates in many therapeutic areas from discovery to early clinical development. This support has included PK/TK/PD (GLP/non-GLP) study design, study direction, bioanalytical assay evaluation, translational PK/PD analysis including first-in-human dose and modeling and simulation supported dose regimen prediction, and reporting to support IND submission. Aaron has expertise in ADCs, bispecifics, CAR-T and mAbs, exciting areas in Model-informed Drug Development. Aaron is also fluent in Japanese.